Treatment of severe, uncontrolled eosinophilic asthma: Where we are headingBiomarkersendotypeseosinophilinflammationIL-5phenotypesObjective: We sought to highlight how our understanding of the pathophysiology of severe asthma has evolved over time and discuss the role of biomarkers in treatment advances and...
FASENRA® (benralizumab) is an add-on maintenance treatment for patients 6 and older who are diagnosed with severe eosinophilic asthma.
FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
*IQVIA National Prescription Audit from January 2023 to December 2023 for all indications combined. NUCALA is indicated for the add-on treatment of patients 6+ with severe eosinophilic asthma (SEA). Not for acute bronchospasm or status asthmaticus....
“Many patients with severe eosinophilic asthma experience debilitating symptoms and face increased risk of emergency room visits, hospitalisations and death, despite current treatments,” said asthma specialist Tim Harrison of Nottingham University, one of the Fasenra clinical investigators. “I look f...
Patients with severe eosinophilic asthma have exaggerated eosinophilopoiesis in the bronchial mucosa that is not affected by treatment with low-dose of mepolizumab [1]. The above observations may explain why our patients did not fully responsd to mepolizumab despite diminished circulating eosinophils. ...
identified just one paper evaluating the long-term clinical and economic impact of adding MEP to standard treatments with ICS and other controller medications on severe eosinophilic asthmatic US patients5. Despite the significant improvement in quality of life, the estimated cost-effectiveness of MEP ...
Severe asthma is associated with substantial morbidity, mortality, and health-care costs.1Recurrent asthma exacerbations are a major problem in some patients and can predominate in a subgroup with eosinophilic airway inflammation.2Mepolizumab—a humanised monoclonal antibody against interleukin 5—selectively...
Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial Clin Exp Allergy, 44 (2014), pp. 508-516 Google Scholar 115. Nair P., Gaga M., Zervas E., Alagha K., Hargreave F.E., O'Byrne P.M.,...
Tezepelumab is an add-on medicine for the treatment of people aged 12 years or older with severe asthma that is not controlled with their current medicines. In this article, we discuss how tezepelumab may work in different types of asthma, for example allergic asthma, eosinophilic asthma, ...